- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2019
- Events
- Inside Information
- Latest Inside Information
- Archive Overview
- Inside Information 2019
- Inside Information 2018
- Inside Information 2017
- Ad-hoc 2016
- Ad-hoc 2015
- Ad-hoc 2014
- Ad-hoc 2013
- Ad-hoc 2012
- Ad-hoc 2011
- Ad-hoc 2010
- Ad-hoc 2009
- Ad-hoc 2008
- Ad-hoc 2007
- Ad-hoc 2006
- Ad-hoc 2005
- Ad-hoc 2004
- Ad-hoc 2003
- Ad-hoc 2002
- Ad-hoc 2001
- Ad-hoc 2000
- Ad-hoc 1999
- Ad-hoc 1998
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2019
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Q2 2009 Investor Conference Call
Wednesday, July 29, 2009
Start at approx. 2:00 p.m. CEST (12:00 noon GMT)
Interim report for the second quarter of 2009:
Bayer robust in a difficult environment
HealthCare strong - further growth at CropScience - MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent) / EBIT before special items EUR 1,101 million (minus 11.8 percent) / Group net income EUR 532 million (minus 7.3 percent) / Net cash flow EUR 1,399 million (plus 57.4 percent) / Earnings targets for full year 2009 confirmed more
Werner Wenning
CEO of Bayer AG
Klaus Kühn
CFO of Bayer AG
MP3 audio recording (presentation and discussion)
| Presentation charts | Download PDF collect (189 KB) |
| Q2 2009 Analyst and Investor Briefing | Download PDF collect (70 KB) |